Warning Letter — Babikian Healthcare Products CJSC
The FDA issued a Warning Letter to Babikian Healthcare Products CJSC following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects Babikian Healthcare Products CJSC, their manufacturing and quality personnel, and potentially any entities utilizing their drug products in the U.S. market.
A Warning Letter from CDER typically indicates significant deviations from Current Good Manufacturing Practice (CGMP) regulations. This may lead to administrative actions, such as the withholding of product approvals or import alerts, until the firm demonstrates adequate remediation of the observed deficiencies.
Regulatory and QA teams should review current manufacturing protocols to ensure alignment with CGMP standards. Facilities should conduct internal audits focusing on documentation practices and production controls cited in the warning letter to prepare for potential inspections.
FDA Warning Letter issued to: Babikian Healthcare Products CJSC. 09/21/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026
Open in openFDA / FDA.gov